

# Pharmaceutical Pipeline – Key Events in 2018\*

<b>Potential Approvals US/EU</b>	ERLEADA™ (apalutamide) – Non-metastatic prostate cancer (US) ✓	<b>Potential Clinical Data Presentations</b>	XARELTO® – VTE prevention medically ill pts (MARINER) ✓
	JULUCA® (Ralpivirine+dolutegravir FDC ViiV) – HIV (EU) ✓		XARELTO® – Congestive heart failure (COMMANDER) ✓
	SYMTUZA™ – HIV (US) ✓		STELARA® – Ulcerative Colitis ✓
	DARZALEX® – Frontline multiple myeloma non-transplant (US /EU) ✓		Esketamine Nasal spray – Treatment-resistant depression ✓
	XARELTO® – CAD/PAD (US) ✓		ERLEADA™ (apalutamide) – Non-metastatic prostate cancer (SPARTAN) ✓
	INVOKANA® – CANVAS/CANVAS-R–CV outcome (US / EU) ✓		SYMTUZA™ – HIV ✓
	ZYTIGA® – Hormone-naïve metastatic prostate cancer (US) ✓		IMBRUVICA® – Frontline CLL combo w/obinutuzumab (ILLUMINATE) ✓ – Treatment-naive WM combo w/rituximab (iINNOVATE) ✓
	IMBRUVICA® – Treatment-naive WM combo w/rituximab (US) ✓		
TREMFYA® – Psoriasis Patient-Controlled Injector (EU) ✓			
<b>Planned Submissions US/EU</b>	Esketamine Nasal Spray – Treatment-resistant depression (US / EU) ✓	<b>Potential Clinical Data Presentations</b>	HIV Vaccine – HIV (TRAVERSE) ✓
	Erdafitinib – Urothelial cancer (US) ✓		IMBRUVICA® – DLBCL relapsed (PCYC1123) ✓
	ERLEADA™ (apalutamide) – Non-metastatic prostate cancer (EU) ✓		IMBRUVICA® – Frontline CLL (IV fixed duration) (PCYC1142) ✓
	IMBRUVICA® – Frontline CLL combo w/obinutuzumab (US ✓ / EU) ✓		DARZALEX® – Frontline multiple myeloma transplant (GRIFFIN) MRD and safety ✓
	IMBRUVICA® – Treatment-naive WM combo w/rituximab (US ✓ / EU) ✓		
	OPSUMIT® – Chronic thromboembolic PH (US /EU) ✓		
	TREMFYA® – Psoriasis Patient-Controlled Injector (US / EU) ✓		<b>Phase 2</b>
STELARA® – Ulcerative Colitis (US)			

✓ = Achieved

\* This information is accurate as of October 16, 2018 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.